Natera, Inc.
NTRACIK 0001604821 · last filing Jul 8, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
0 bought / 20,800 sold
net −20,800 sh · −$5.67M
- buys
- 0
- sells
- 16
- insiders active
- 3
Filing tape
Filed Wed, Jul 8, 2026
- −1,000 sh · $280.0K
Rabinowitz Matthew — EXECUTIVE CHAIRMAN · Director
- Sold1,000Common Stock@ $280.00→ 4,000 held
Filed Mon, Jul 6, 2026
- −3,000 sh · $818.7K
Moshkevich Solomon — PRESIDENT, CLINICALDIAGNOSTICS
- Sold100Common Stock@ $267.19→ 137,543 held
- Sold2,600Common Stock@ $272.99→ 134,943 held
- Sold300Common Stock@ $274.06→ 134,643 held
- −16,800 sh · $4.57M
Rabinowitz Daniel — SEC. AND CHIEF LEGAL OFFICER
- Sold1,568Common Stock@ $266.79→ 187,526 held
- Sold3,705Common Stock@ $268.11→ 183,821 held
- Sold1,932Common Stock@ $268.99→ 181,889 held
- Sold484Common Stock@ $269.87→ 181,405 held
- Sold1,357Common Stock@ $270.96→ 180,048 held
- Sold454Common Stock@ $272.14→ 179,594 held
- Sold500Common Stock@ $274.19→ 179,094 held
- Sold1,100Common Stock@ $275.20→ 177,994 held
- Sold1,400Common Stock@ $276.24→ 176,594 held
- Sold2,045Common Stock@ $277.29→ 174,549 held
- Sold1,955Common Stock@ $278.25→ 172,594 held
- Sold300Common Stock@ $278.77→ 172,294 held
Insiders on this tape
- Rabinowitz MatthewEXECUTIVE CHAIRMAN · Director
- Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
- Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.